00:24 , Apr 12, 2019 |  BC Innovations  |  Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
07:00 , May 26, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Autoimmune disease Autoimmune disease CD28; inducible T cell co-stimulator ligand (ICOSLG; B7-H2) In vitro and cell culture studies suggest inhibiting interactions between B7-H2 and CD28 could help treat autoimmune disease. An...
07:00 , May 26, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

This week in therapeutics Various Colorectal cancer; colitis; inflammatory bowel disease (IBD) NLR family pyrin domain containing 6 (NLRP6; NALP6) Mouse studies suggest increasing NLRP6 levels could help prevent IBD- and colitis-associated colorectal cancer. Nlrp6...